Business Highlights - Approximately 35 million patients are considered statin intolerant in the U S, Japan, and the EU[8] - Statin intolerance impacts up to 20% of individuals treated with a statin[8, 12] - CLEAR Outcomes trial has enrolled over 14,000 patients and is powered for success[12] - The CLEAR Outcomes trial expects a high baseline LDL-C of approximately 140 mg/dL[12] Operational Performance - Over 8,600 doctors are writing at least one prescription for Esperion's medicines[15] - More than 3,300 patients are taking Esperion's medicines every week[15] - Over 420,000 seven-day starter packs have been requested and received[15] - New-to-brand statin prescriptions are down 9% year-to-date 2021 compared to year-to-date 2020 due to COVID-19 impacts[17] Financial Results & Guidance - U S Net Product Sales increased 14 6% quarter over quarter[23] - Royalty revenues from DSE were $8 2 million in the quarter[23] - Ex-U S Collaboration Milestones were $3 3 million[23] - The company anticipates FY 2021 revenues between $120 - $130 million[26]

FORWARD-LOOKNG STATEMENTS & DISCLOSURES MAY 3, 2022 © 2022 Esperion. All Rights Reserved – For investor audience only WHEN DO YOU PLAN TO GET YOUR NEXT CHOLESTEROL TEST? This presentation contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding marketing strategy and commercialization plans, current and planned operational expenses, future operations, commercial products, clinical development, including the timing ...

WHEN DO YOU PLAN TO GET YOUR NEXT CHOLESTEROL TEST? FORWARD-LOOKNG STATEMENTS & DISCLOSURES This presentation contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding marketing strategy and commercialization plans, restructuring and current and planned operational expenses, future operations, commercial products, clinical development including the timing, designs and plans for the CLEAR Outcomes study and its resu ...

Second Quarter 2024 Business Update August 8, 2024 © 2024 Scholar Rock, Inc. All rights reserved. 1 Forward-Looking Statements Various statements in this presentation concerning the future expectations, plans and prospects of Scholar Rock Holding Corporation and Scholar Rock, Inc. (collectively, "Scholar Rock"), including without limitation, Scholar Rock's expectations regarding its strategy, its product candidate selection and development timing, including timing for the initiation of and reporting results ...

Dedicated to Dramatically Improving the Lives of Patients with SMA Q1 2025 Business Update May 14, 2025 © 2025 Scholar Rock, Inc. All rights reserved. Q1 Earnings Call | TO P I C | S P E A K E R | | --- | --- | | Scholar Rock Next Phase of Growth | David L. Hallal | | | Chief Executive Officer | | R&D Progress | Akshay Vaishnaw, M.D., Ph.D | | | President of R&D | | Commercial Readiness | Keith Woods | | | Chief Operating Officer | | Company Financials | Vikas Sinha | | | Chief Financial Officer | | Q&A Ses ...

Precision oncology medicines powered by synthetic lethal insights Corporate Presentation May 2025 Disclaimer Statements contained in this presentation regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as "anticipates," "believes," "expects," "intends," "plans," "potential," "projects," "would" and "future" or similar expressions are intended to identify forward-looking statements ...

Zev A. Wainberg, Alisha H. Bent, Victor Moreno, Manuel Pedregal, Rutika Mehta, Eric Chen, Jorge Ramon-Patino, Ryan H. Moy, Brian Madajewski, Adam Petrone, Pooja Adesara-Patel, Yajun Liu, Xizi Sun, Elia Aguado-Fraile, Paul Basciano, Sunantha Sethuraman, Nathan Hawkey, Elisa Fontana DECLARATION OF INTERESTS PHASE 1 STUDY OF THE PKMYT1 INHIBITOR LUNRESERTIB (LUNRE) IN COMBINATION WITH FOLFIRI IN ADVANCED GASTROINTESTINAL CANCERS (MINOTAUR STUDY) Elisa Fontana, MD, PhD Sarah Cannon Research Institute UK, London ...

Financial Performance Highlights - For the full year 2015, Caesars Entertainment Corporation (CEC) + Caesars Entertainment Operating Company (CEOC) net revenues reached $9053 million, a 6% increase year-over-year[18] - Adjusted EBITDA for CEC + CEOC in FY2015 was $2399 million, up 42% year-over-year[18] - Continuing CEC's net revenues for FY2015 were $4496 million, a 15% increase year-over-year[18] - Continuing CEC's Adjusted EBITDA for FY2015 was $1270 million, up 46% year-over-year[18] - Enterprise-wide EBITDA margin expansion was achieved through cost-saving initiatives, with an incremental $350 million of EBITDA delivered in FY2015[22] Segment Performance - Caesars Growth Partners (CGP) reported net revenue of $600 million in 4Q 2015, a 14% increase year-over-year, and Adjusted EBITDA of $157 million, up 52% year-over-year[58] - Caesars Entertainment Resort Properties (CERP) saw net revenue increase by 3% to $517 million in 4Q 2015, with Adjusted EBITDA up 41% to $145 million[55] - Caesars Interactive Entertainment (CIE) experienced a 33% year-over-year increase in net revenue, reaching $208 million, and a 67% increase in Adjusted EBITDA to $77 million[64] - CEOC's Adjusted EBITDA increased by 44% with margins up 698 basis points year-over-year[68] Strategic Initiatives and Investments - The company is investing in Las Vegas hotel room upgrades, with over 4800 rooms in Las Vegas and over 5700 enterprise-wide expected to be renovated in 2016[27] - A gaming innovation strategy is in motion, focusing on re-energizing the core slot player and engaging Millennial/Generation X customers[48]

4Q & FY 2016 Earnings FEBRUARY 14, 2017 FORWARD LOOKING STATEMENTS CAESARS ENTERTAINMENT CORPORATION USE OF NON-GAAP MEASURES The following non-GAAP measures will be used in the presentation and discussed on the conference call which this presentation accompanies: Definitions of these non-GAAP measures, reconciliations to their nearest GAAP measures, and the reasons management believes these measures provide useful information for investors, can be found on Slide 4 and in the Appendix to this presentation, ...

Agenda Kymera's Immunology Strategy Nello Mainolfi, PhD, Founder, President and Chief Executive Officer Oral Medicines with Biologics-like Activity Immunology Innovation Day May 9, 2025 STAT6 (KT-621) Update Jared Gollob, MD, Chief Medical Officer IRF5 (KT-579): Drugging a Genetically Validated Target Veronica Campbell, Senior Director, Immunology Question and Answer Session Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigati ...